Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00203892 · ClinicalTrials.gov registry record · Phase 1
Study of CAP1-6D in Patients With Locally Advanced or Surgically Resected Pancreatic Adenocarcinoma
A Phase 1 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT00203892 is a Phase 1 study that has completed, run by University of Chicago. The registered enrollment target is 23 participants.
The verdict
NCT00203892, a Phase 1 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the experimental vaccine "modified CEA peptide CAP 1 -6D" (mCEA) can produce an immune response in patients with pancreatic cancer who have received chemotherapy and radiation therapy.
Interventions
- BIOLOGICAL modified CEA peptide (10mcg)
- BIOLOGICAL modified CEA peptide (100mcg)
- BIOLOGICAL modified CEA peptide (1000mcg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2003-04 |
| Est. Completion | 2012-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00203892
The ClinicalTrials.gov registry entry for NCT00203892 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which modified CEA peptide (10mcg) is the first listed.
NCT00203892 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00203892 about?
NCT00203892 is a clinical study titled "Study of CAP1-6D in Patients With Locally Advanced or Surgically Resected Pancreatic Adenocarcinoma". The purpose of this study is to determine whether the experimental vaccine "modified CEA peptide CAP 1 -6D" (mCEA) can produce an immune response in patients with pancreatic cancer who have received chemotherapy and radiation therapy.
What is the current status of trial NCT00203892?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2003-04. Estimated completion is 2012-05.
What interventions are being tested in trial NCT00203892?
The interventions under investigation include: modified CEA peptide (10mcg) (BIOLOGICAL), modified CEA peptide (100mcg) (BIOLOGICAL), modified CEA peptide (1000mcg) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00203892?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.